The timing would be rather propitious as next quarters results will most certainly be given a massive boost as a result of the USPSTF's revised rating and subsequent insurer adoption. This little company could grow into a behemoth diagnostic powerhouse with the government on tap for 85% of their income in the very near future.
Adam, be sure to read the WHOLE report next time. The change in wording makes it identical to all other "A" rated diagnostics and as such, prevents (remember what USPSTF stands for) the insurers from putting up roadblocks to coverage from one approach vs the other. If you read the entire thing you see that they most effectively skewer both Colonoscopy and FIT before going on to give them "A" ratings as well. Now CG will sit in stead with them. End of debate, end of subjectively interpreted insurance reimbursement policies. I hope this helps you "understand" Adam
FD: I own over 50,000 shares of that one with an average price below a buck.
Combined together with my EXAS holdings (which have tripled in number after reversing my short from 22 earlier this spring), Im having a VERY NICE DAY - FINALLY!! GLTA!!
The assumption here of course is that they are going to conduct another secondary. This could be the case. On the other hand, with EU approval, it is not unlikely that they are in a position to negotiate an equity stake with a bigger pharma partner - in which case we would see a substantial rise in our market cap and as a reflection, in the price of our shares. Its basically too late to throw in the towel now. You'd have to be a complete and total idiot - or an insider who KNOWS a PIPE deal is coming. If so, we should all hope that the investor is a PARTNER